These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 22151023)
21. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. Ballantyne CM; Raichlen JS; Cain VA J Am Coll Cardiol; 2008 Aug; 52(8):626-32. PubMed ID: 18702965 [TBL] [Abstract][Full Text] [Related]
22. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design. Lablanche JM; Danchin N; Farnier M; Tedgui A; Vicaut E; Alonso J; Crean P; Leone A; Morais J; Santini M; Licour M; Farah M; Tardif JC Arch Cardiovasc Dis; 2008 Jun; 101(6):399-406. PubMed ID: 18809153 [TBL] [Abstract][Full Text] [Related]
23. Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes. Mori Y; Kuriyama G; Tanaka T; Tajima N Endocrine; 2009 Dec; 36(3):412-8. PubMed ID: 19834827 [No Abstract] [Full Text] [Related]
24. Do the lipid responses to rosuvastatin and atorvastatin differ between Chinese and Caucasians? Comparison of the DISCOVERY-Hong Kong study with other DISCOVERY studies. Hu M; Lui SS; Ko GT; Tomlinson B Int J Cardiol; 2013 Oct; 168(3):3071-3. PubMed ID: 23642826 [No Abstract] [Full Text] [Related]
25. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. Rawlings R; Nohria A; Liu PY; Donnelly J; Creager MA; Ganz P; Selwyn A; Liao JK Am J Cardiol; 2009 Feb; 103(4):437-41. PubMed ID: 19195498 [TBL] [Abstract][Full Text] [Related]
26. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. Hong YJ; Jeong MH; Hachinohe D; Ahmed K; Choi YH; Cho SH; Hwang SH; Ko JS; Lee MG; Park KH; Sim DS; Yoon NS; Yoon HJ; Kim KH; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Kang JC Circ J; 2011; 75(2):398-406. PubMed ID: 21157106 [TBL] [Abstract][Full Text] [Related]
27. Impact of statins on glucose metabolism--a matter of debate. Anagnostis P; Athyros VG; Karagiannis A; Mikhailidis DP Am J Cardiol; 2011 Jun; 107(12):1866. PubMed ID: 21640222 [No Abstract] [Full Text] [Related]
28. NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin. Satoh M; Tabuchi T; Itoh T; Nakamura M Clin Sci (Lond); 2014 Feb; 126(3):233-41. PubMed ID: 23944632 [TBL] [Abstract][Full Text] [Related]
29. Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes. Ramachandran S; Saraf S; Shetty C; Capps N; Bailey C Ann Clin Biochem; 2011 Jan; 48(Pt 1):75-8. PubMed ID: 21115572 [TBL] [Abstract][Full Text] [Related]
31. Relationship between statin type and responsiveness to clopidogrel in patients treated with percutaneous coronary intervention: a subgroup analysis of the CILON-T trial. Suh JW; Cha MJ; Lee SP; Chae IH; Bae JH; Kwon TG; Bae JW; Cho MC; Rha SW; Kim HS J Atheroscler Thromb; 2014; 21(2):140-50. PubMed ID: 24140730 [TBL] [Abstract][Full Text] [Related]
33. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554 [TBL] [Abstract][Full Text] [Related]
34. Effect of atorvastatin vs. rosuvastatin on cardiac sympathetic nerve activity in non-diabetic patients with dilated cardiomyopathy. Tsutamoto T; Sakai H; Ibe K; Yamaji M; Kawahara C; Nakae I; Fujii M; Yamamoto T; Horie M Circ J; 2011; 75(9):2160-6. PubMed ID: 21737951 [TBL] [Abstract][Full Text] [Related]
35. Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study. Kipnes MS; Roth EM; Rhyne JM; Setze CM; Lele A; Kelly MT; Sleep DJ; Stolzenbach JC Clin Drug Investig; 2010; 30(1):51-61. PubMed ID: 19995098 [TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy--the PEARL randomized cross-over study. Pelliccia F; Rosano G; Marazzi G; Vitale C; Spoletini I; Franzoni F; Speziale G; Polacco M; Greco C; Gaudio C Eur J Pharmacol; 2014 Feb; 725():18-22. PubMed ID: 24444439 [TBL] [Abstract][Full Text] [Related]
37. Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Bergheanu SC; Reijmers T; Zwinderman AH; Bobeldijk I; Ramaker R; Liem AH; van der Greef J; Hankemeier T; Jukema JW Curr Med Res Opin; 2008 Sep; 24(9):2477-87. PubMed ID: 18655752 [TBL] [Abstract][Full Text] [Related]
38. Statin wars: emphasis on potency vs event reduction and safety? Lavie CJ; Milani RV; O'Keefe JH Mayo Clin Proc; 2007 May; 82(5):539-42. PubMed ID: 17493417 [No Abstract] [Full Text] [Related]
39. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective. Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996 [TBL] [Abstract][Full Text] [Related]
40. Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database. Palmer MK; Nicholls SJ; Lundman P; Barter PJ; Karlson BW Eur J Prev Cardiol; 2013 Dec; 20(6):1080-7. PubMed ID: 23644489 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]